LEADER 03906nam 22006015 450 001 9910300440003321 005 20200630024611.0 010 $a981-10-7691-X 024 7 $a10.1007/978-981-10-7691-6 035 $a(CKB)4100000001795050 035 $a(DE-He213)978-981-10-7691-6 035 $a(MiAaPQ)EBC5228472 035 $a(PPN)223953997 035 $a(EXLCZ)994100000001795050 100 $a20180116d2018 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMid-size Drugs Based on Peptides and Peptidomimetics $eA New Drug Category /$fby Hirokazu Tamamura, Takuya Kobayakawa, Nami Ohashi 205 $a1st ed. 2018. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2018. 215 $a1 online resource (XVII, 100 p. 40 illus., 32 illus. in color.) 225 1 $aSpringerBriefs in Pharmaceutical Science & Drug Development,$x1864-8118 311 $a981-10-7690-1 320 $aIncludes bibliographical references at the end of each chapters. 327 $a1. Introduction of Mid-Size Drugs and Peptidomimetics -- 2. Chloroalkene Dipeptide Isosteres as Peptidomimetics -- 3. Conformational-restricted Cyclic Peptides -- 4. Peptidomimetics that Mimic Secondary Structures of Peptides -- 5.Peptidomimetics that Mimic Tertiary Structures of Peptides -- 6. Conjugated Compounds Involving Peptides -- 7. Summary and Future Perspectives of Researches on Mid-Size Drugs. 330 $aThis brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region between low- and high-molecular-weight compounds. Thus, mid-size drugs such as peptide compounds are being focused on. To date, several peptidomimetics that mimic primary, secondary, and tertiary structures of peptides have been developed to maintain and improve biological activities and actions of peptides. In this book, the features and advantages of mid-size drugs are described in detail. In addition, the merits of utilizing peptidomimetics in the development of mid-size drugs are referred to. Understanding such peptide-derived mid-size drugs will lead to a comprehensive expansion of medicinal chemistry. 410 0$aSpringerBriefs in Pharmaceutical Science & Drug Development,$x1864-8118 606 $aMedicinal chemistry 606 $aPharmaceutical technology 606 $aOrganic chemistry 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aOrganic Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C19007 615 0$aMedicinal chemistry. 615 0$aPharmaceutical technology. 615 0$aOrganic chemistry. 615 14$aMedicinal Chemistry. 615 24$aPharmaceutical Sciences/Technology. 615 24$aOrganic Chemistry. 676 $a540 700 $aTamamura$b Hirokazu$4aut$4http://id.loc.gov/vocabulary/relators/aut$0784597 702 $aKobayakawa$b Takuya$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aOhashi$b Nami$4aut$4http://id.loc.gov/vocabulary/relators/aut 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300440003321 996 $aMid-size Drugs Based on Peptides and Peptidomimetics$92022346 997 $aUNINA